CCL5 activates β-catenin/STAT3 signaling to promote the self-renewal and tumor metastasis of prostate CSCs (PCSCs), and its knockdown significantly inhibits the metastasis of prostate cancer and the self-renewal capacity of PCSCs [110]. Here, CCL5 is linked to neoplasm.